Werewolf Therapeutics (NASDAQ:HOWL) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a research note issued to investors on Monday, Benzinga reports. HC Wainwright currently has a $15.00 price target on the stock. HC Wainwright also issued estimates for Werewolf Therapeutics’ Q2 2024 earnings at ($0.40) EPS, Q3 2024 earnings at ($0.36) EPS, Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.52) EPS, FY2025 earnings at ($0.91) EPS, FY2026 earnings at ($1.11) EPS, FY2027 earnings at ($1.89) EPS and FY2028 earnings at ($1.34) EPS.

Separately, JMP Securities began coverage on shares of Werewolf Therapeutics in a research report on Wednesday, April 3rd. They issued a mkt outperform rating and a $12.00 price target on the stock.

Werewolf Therapeutics Stock Up 1.6 %

HOWL opened at $5.57 on Monday. The company has a market capitalization of $241.46 million, a PE ratio of -5.11 and a beta of 0.71. The firm has a 50-day simple moving average of $6.09 and a two-hundred day simple moving average of $4.74. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.29. Werewolf Therapeutics has a 52 week low of $1.57 and a 52 week high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.10. Werewolf Therapeutics had a negative return on equity of 36.43% and a negative net margin of 256.33%. The company had revenue of $1.50 million during the quarter, compared to analyst estimates of $2.75 million. Analysts forecast that Werewolf Therapeutics will post -1.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. PFM Health Sciences LP boosted its position in Werewolf Therapeutics by 35.6% in the 4th quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock valued at $13,387,000 after buying an additional 909,895 shares during the period. Denali Advisors LLC bought a new position in Werewolf Therapeutics in the first quarter worth approximately $172,000. Lighthouse Investment Partners LLC bought a new position in Werewolf Therapeutics in the fourth quarter worth approximately $87,000. Certuity LLC purchased a new position in shares of Werewolf Therapeutics during the fourth quarter valued at $39,000. Finally, Financial Perspectives Inc raised its holdings in shares of Werewolf Therapeutics by 80.0% in the fourth quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock valued at $26,000 after acquiring an additional 3,000 shares in the last quarter. 64.84% of the stock is owned by institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.